The HCT/P Modernization Act of 2025

Where This Stands

Introduced

Committee

Floor Vote

Passed

Signed

Currently in_committee. The next step in the legislative lifecycle is Floor Vote.

Last action

Referred to the House Committee on Energy and Commerce.Jan 13, 2025

Lead sponsor

Dan Crenshaw

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

The Frame

What this does

The bill proposes changes to the regulatory framework for medical products derived from human cells and tissues, which could impact the approval process, safety standards, and market access for regenerative medicine and tissue-based therapies.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Biotechnology and pharmaceutical companies

These entities develop and manufacture products that fall under HCT/P regulatory oversight.

House Committee on Energy and Commerce

The committee is responsible for reviewing and determining the legislative path of the bill.

What changed

Current stage: in_committee.

What's next

Floor Vote.

Summary

This proposed federal bill aims to update regulations regarding Human Cells, Tissues, and Cellular and Tissue-Based Products (s). It has been introduced in the House of Representatives and is currently under review by the Committee on Energy and Commerce.

Why It Matters

The bill proposes changes to the regulatory framework for medical products derived from human cells and tissues, which could impact the approval process, safety standards, and market access for regenerative medicine and tissue-based therapies.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

What are HCT/Ps?

s stands for Human Cells, Tissues, and Cellular and Tissue-Based Products, which are medical products containing or consisting of human cells or tissues.

What is the current status of this bill?

The bill has been introduced and referred to the House Committee on Energy and Commerce.